Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Acadia Pharmaceutica (ACAD)

Acadia Pharmaceutica (ACAD)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Lifshitz Law Firm, P.C. Announces Investigations of 3D Systems Corp. (NYSE: DDD), Acadia Pharmaceuticals, Inc. (NasdaqGS: ACAD), ChemoCentryx, Inc. (NasdaqGS: CCXI), and Peloton Interactive, Inc (NasdaqGS: PTON)

EQNX::TICKER_START EQNX::TICKER_END

DDD : 29.79 (+2.20%)
ACAD : 17.41 (+2.77%)
CCXI : 19.21 (+5.55%)
PTON : 92.07 (-0.62%)
Acadia Pharmaceuticals to Present at the Canaccord Genuity 41st Annual Growth Conference on August 12, 2021

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the Canaccord Genuity 41st Annual Growth Conference on Thursday, August 12, 2021, at 3:00 p.m. Eastern Time.

ACAD : 17.41 (+2.77%)
ACADIA (ACAD) Q2 Earnings Beat, Revenues Miss Estimates

ACADIA's (ACAD) loss narrows in the second quarter of 2021 while its revenues miss the mark. The company has reduced its revenue guidance for 2021. Shares down in after-hours trading.

TECH : 511.45 (-5.09%)
ACAD : 17.41 (+2.77%)
SPRO : 19.47 (+3.95%)
COCP : 1.0600 (+2.91%)
Acadia Pharmaceuticals (ACAD) Reports Q2 Loss, Misses Revenue Estimates

Acadia (ACAD) delivered earnings and revenue surprises of 10.00% and -9.27%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

ACAD : 17.41 (+2.77%)
Acadia: Q2 Earnings Snapshot

SAN DIEGO (AP) _ Acadia Pharmaceuticals Inc. (ACAD) on Wednesday reported a loss of $43.9 million in its second quarter.

ACAD : 17.41 (+2.77%)
Acadia Pharmaceuticals Reports Second Quarter 2021 Financial Results

--- Fiscal year 2021 revenue guidance reduced to $480 to $515 million

ACAD : 17.41 (+2.77%)
The New England Journal of Medicine Publishes Results from the Phase 3 HARMONY Study Evaluating Pimavanserin in Patients with Dementia-Related Psychosis

--- Pimavanserin met the secondary endpoint of significantly reducing trial discontinuation for any reason by 2.2 fold

ACAD : 17.41 (+2.77%)
Acadia Pharmaceuticals to Announce Second Quarter 2021 Financial Results on August 4, 2021

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report second quarter 2021 financial results on Wednesday, August 4, 2021, after the close of the U.S. financial markets. Acadia's...

ACAD : 17.41 (+2.77%)
Cassava Sciences (SAVA) to Post Q2 Earnings: What's in Store?

Investors will be keen on updates from on its lead candidate, sumifilam, for Alzheimer's disease when Cassava (SAVA) reports Q2 results.

EXAS : 95.00 (-1.06%)
ACAD : 17.41 (+2.77%)
BPMC : 106.36 (-0.23%)
SAVA : 68.53 (+10.64%)
Synlogic's (SYBX) Begins Phase I Study for PKU Treatment

Synlogic (SYBX) initiates phase I study of SYNB1934, a synthetic biotic candidate to treat PKU. The drug is an evolved strain of SYNB1618, another PKU candidate currently undergoing phase II study.

BMRN : 78.62 (+0.03%)
EXAS : 95.00 (-1.06%)
ACAD : 17.41 (+2.77%)
SYBX : 3.05 (-3.79%)

Barchart Exclusives

The Evolution of the Food and Beverage Industry
On this week’s episode of The Food Biz , hosts Kristyn Tarpey and Ryan Nelson are joined by Russ Whitman, Senior Vice President of Urner Barry. Urner Barry is the leader in price reporting for the poultry, egg, meat, and seafood segments of the food industry. Urner Barry’s prices are... Read more

Barchart Futures Commentary

Barchart Futures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar